Vitamin K Administration for Intracranial Hemorrhage with INR 1.7
Yes, administer intravenous vitamin K 5-10 mg regardless of the INR level in patients with warfarin-associated intracranial hemorrhage, even at an INR of 1.7. 1
Rationale and Evidence
The 2022 AHA/ASA guideline explicitly states that "Intravenous vitamin K at a dose of 5 to 10 mg should be administered regardless of the type of coagulation factor replacement (PCC or plasma) in patients with VKA-related ICH" 1. This recommendation applies to all patients with VKA-associated intracranial bleeding, not just those with INR >2.0.
Why Vitamin K is Critical Even at Lower INRs
Prevents INR rebound: Case reports demonstrate that when PCC is given without vitamin K, initial INR normalization can be followed by rebound elevation at 12-24 hours, with one patient experiencing hematoma enlargement and clinical deterioration 1
Sustained reversal: Vitamin K provides durable anticoagulation reversal beyond the short half-life of prothrombin complex concentrates, which is essential for preventing secondary hemorrhage expansion
Mortality benefit: Guideline-concordant administration of both PCC and vitamin K within 8 hours is associated with a two-fold decrease in 7-day mortality (OR 2.15) in all bleeding patients and three-fold decrease (OR 3.23) specifically in intracranial hemorrhage 2
Management Algorithm for INR 1.7
Immediate Actions:
Administer IV vitamin K 5-10 mg immediately upon diagnosis 1, 3
- Give slowly, not exceeding 1 mg per minute 3
- Oral route is NOT appropriate for intracranial hemorrhage
Consider PCC administration at reduced dosing:
Recheck INR 30 minutes after PCC infusion and at 6-8 hours to assess response 1, 4
Clinical Context
While the landmark INCH trial excluded patients with INR <2.0, observational data from 88 patients with warfarin-related ICH and INR >1.2 demonstrated survival benefit with PCC over FFP 1. Additionally, recent data shows that VKA use with INR >1.7 significantly increases symptomatic intracranial hemorrhage risk (adjusted OR 1.88) compared to no anticoagulation 5.
Critical Pitfalls to Avoid
- Do NOT withhold vitamin K based on the "low" INR—any elevation above normal in the setting of intracranial hemorrhage warrants reversal
- Do NOT use subcutaneous vitamin K—it has unpredictable absorption and slower onset 6
- Do NOT use oral vitamin K in acute intracranial hemorrhage—this is only appropriate for asymptomatic INR elevations 6
- Do NOT give vitamin K alone without considering PCC if rapid reversal is needed, as vitamin K takes 6-8 hours for effect 3
The evidence consistently supports aggressive reversal even at borderline INR elevations because intracranial hemorrhage represents life-threatening bleeding where any coagulopathy increases mortality risk.